Galantamine treatment of vascular dementia: A randomized trial

Neurology

Volumn 69, Issue 5, 2007, Pages 448-458

  Auchus, A P ^a   Brashear, H R ^b   Salloway, S ^c   Korczyn, A D ^d   De Deyn, P P ^e   Gassmann Mayer, C ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c BUTLER HOSPITAL   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; PLACEBO; ACETYLCHOLINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING INVENTORY; ANOREXIA; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CLINICIAN INTERVIEW BASED ON IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FALLING; FEMALE; FUNCTIONAL ASSESSMENT; HEART INFARCTION; HUMAN; HYPERTENSION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NAUSEA; NEUROPSYCHIATRIC INVENTORY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; ADULT; BRAIN; BRAIN LEVEL; COGNITIVE DEFECT; CONVALESCENCE; DRUG EFFECT; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ACETYLCHOLINE; ACTIVITIES OF DAILY LIVING; ADULT; AGED; BEHAVIORAL SYMPTOMS; BRAIN; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 34547814166     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000266625.31615.f6     Document Type: Article

References (31)

1. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000;393:165-170.
2. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994;5:163-167.
3. Grantham C, Geerts H. The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci 2002;203-204:131-136.
4. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003;60:1183-1185.
5. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 2002;359:1283-1290.
6. Lojkowska W, Ryglewicz D, Jedrzejczak T, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003;215:119-126.
7. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765-1782.
8. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CV. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003;10:633-640.
9. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479-486.
10. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-2330.
11. Scheltens P, Brashear HR. Galantamine for the treatment of vascular dementia: patient demographics. J Neurol Sci 2004;266:161-162.
12. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international workshop. Neurology 1993;43:250-260.
13. Gold G, Bouras C, Canuto A, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 2002;159:82-87.
14. Rockwood K, Davis H, MacKnight C, et al. The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Can J Neurol Sci 2003;30:237-243.
15. van Straaten EW, Scheltens P, Knol DL, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003;34:1907-1912.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
18. Mohs RC. Administration manual for the Alzheimer's Disease Assessment Scale. 1994 revised ed. New York: Mount Sinai School of Medicine, 1994.
19. Hachinski VC, Iliff LD, Zilkha E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
20. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997;49:1096-1105.
21. Galasko D. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11 (suppl 2):S33-S39.
22. Joffres C, Graham J, Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr 2000;12:403-13.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
24. Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992;40:1221-1226.
25. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997;227:813-817.
26. Bowler JV, Eliasziw M, Steenhuis R, et al. Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch Neurol 1997;54:697-703.
27. Blacker D, Albert MS, Bassett SS, et al. Reliability and validity of NINDCS-ADRDA criteria for Alzheimer's disease: the National Institute of Mental Health Geriatrics Initiative. Arch Neurol 1994;51:1198-1204.
28. Bodick N, Forette F, Hadler D, et al. Protocols to demonstrate slowing of Alzheimer's disease progression: position paper from the International Working Group on Harmonisation of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11 (suppl 3):50-53.
29. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
30. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471-481.
31. Ferris S, Gauthier S. Cognitive outcome measures in vascular dementia. In: Erkinjuntii T, Gauthier S, eds. Vascular cognitive impairment. London: Martin Duniz, 2002:395-400.